2012 Fourth Vaccine Conference
- This entry lacks an overview map . Supplementing related content makes the entry more complete and can be upgraded quickly. Come on!
- Name
- 2012 Fourth Vaccine Conference
- City
- Beijing
- Hosting place
- Beijing International Convention Center
- Industry
- Biology / Medicine / Health
- The 4th Vaccine Conference 2012, sponsored by the Foreign Talent Information Research Center of the State Administration of Foreign Experts Affairs and China Pharmaceutical Biotechnology Association, and hosted by Biotec International Conference (Dalian) Co., Ltd., will be held in Beijing on March 26-28, 2012 .
|
|
|
|
|
|
|
|
|
|
- In addition to the main forum, the Vaccine Conference will organize global vaccination landscapes and prospects, breakthroughs in vaccine science and technology, vaccine research and development platforms based on cell biology and molecular biology, discovery and development of new human vaccines, and animal applications 8 science and technology forums and branch activities including vaccine production, vaccine development, clinical trial vaccine production, manufacturing and quality control / quality assurance.
- The meeting was honored to invite Dr. Rene Labatut, Vice President of Global Technology of Sanofi-Pasteur, France, Dr. William Strohl, Vice President of Johnson & Johnson, Dr. Patrick Baeuerle, Chief Scientist of Micromet, Germany, Dr. Tilahun Yilma, Member of the American Academy of Sciences, and Senior of Novavax, USA Dr. John J. Trizzino, Vice President, Dr. Alan Liss, Director of the US Food and Drug Administration, Dr. Jonathan J Liu, R & D Director of MedImmune, USA, and Dr. Stephen Lockhart, Senior Vice President of Emergent BioSolutions in the UK, participated in the exchanges.
- This conference will provide participants with cutting-edge scientific and technological information, relay industry development trends and latest trends, and is an annual event in the field of vaccine research.
- Session 1: Global vaccination landscape and outlook
- Topic 100: A new generation of vaccines looking ahead for decades
- Topic 101: Development of universal and traveller vaccination against seasonal and influenza and major infectious diseases
- Topic 102: Immunization programmes to eradicate poverty in developing countries
- Topic 103: Key Vaccination Issues and Public Health in Developed Countries
- Session 104: Evaluation of Vaccine Effectiveness and Safety, Durability, Safety of New Vaccines, Austin, Ethical Issues and Public Recognition
- Session 2: Breakthroughs in Vaccine Science and Technology
- Topic 210: Innate / Adaptive Immunization and Vaccine Design to Development
- Session 211: Systems Biology, Genomics, and Proteomics for Vaccine Discovery and Development
- Topic 212: Reverse Vaccines and Evidence-Based Vaccines
- Session 213: Bioinformatics in Vaccines
- Session 214: Application of Structural-Based Antigen Design in Vaccine Discovery
- Session 215: Application of Biomarkers in Vaccine Discovery and Development
- Topic 216: Controlling host pathogen interactions to make vaccines
- Topic 217: Application of vaccines in personalized medicine
- Topic 218: Application in animal models of vaccine development
- Topic 220: Virus-like particles, nanotechnology and vaccines
- Topic 221: General Vaccine Technology
- Topic 222: Cytokine networks in vaccine design
- Topic 223: Production of vaccines for genetically modified plants
- Topic 224: TOLL-LIKE Receptor Vaccine Development Technology
- Topic 225: Safety, cost, efficiency and impact of vaccination
- Session 3: Vaccine R & D Platform Based on Cell Biology and Molecular Biology
- Topic 300: Making better attenuated and inactivated vaccines
- Topic 301: Immune boosters, vectors, adjuvants and vaccine design
- Topic 302: Application of a Cell-Based Vaccine Technology Platform
- Topic 303: New vaccine delivery technologies
- Topic 304: Design and development of new subunit vaccines
- Topic 305: Use of recombinant vector vaccines
- Topic 306: Recombinant Nucleic Acid Vaccine Technology
- Topic 307: Carbohydrate or polysaccharide vaccines
- Topic 308: Peptide vaccines
- Session 4: Discovery and Development of New Human Vaccines
- Topic 410: Meningitis vaccine
- Topic 411: Hepatitis Vaccines
- Topic 412: HIV / AIDS / SIV vaccine development
- Topic 413: Influenza and SARS vaccines
- Topic 414: Dengue vaccine
- Topic 415: Vaccines against rotavirus, chickenpox and shingles
- Session 416: Ebola, Marburg, West Nile and Alphaviral Encephalitides vaccine development
- Topic 417: Foot-and-Mouth Disease and Hanta virus vaccine development
- Topic 418: Japanese Encephalitis, Junin, Hendra and Nipah Virus Vaccines
- Special Topic 419: Measles, Tick-Bone Encephalitis Vaccine and Vaccines for Other Viral Infections
- Topic 420: Molecular approaches to bacterial vaccines
- Topic 421: Developing vaccines against super bacteria
- Topic 422: Development of vaccines against Klebsiella and Streptococcus pneumoniae
- Session 423: Shigella, Enterotoxigenic Escherichia coli and Urinary Pathogenic Escherichia coli Vaccines
- Topic 424: Burkholderia pseudomallei and Burkholderia pseudomallei vaccines
- Topic 431: Innovative R & D of Malaria Vaccine
- Topic 432: Leishmaniasis and Leptospirosis vaccines
- Topic 433: Antiprotozoal vaccines
- Topic 434: Anti-Schistosomiasis and Toxoplasmosis Vaccines
- Session 4-4: Development of new vaccines for adult prevention
- Topic 4-5: Development of therapeutic vaccines against cancer
- Session 4-6: Anti-inflammatory and Autoimmune Disease Vaccines
- Topic 4-7: Development of vaccines against neurodegeneration and central nervous system
- Topic 4-8: Therapeutic vaccines against addiction
- Session 5: Vaccines for Animals
- Topic 500: Recent breakthroughs in veterinary vaccines
- Session 501: Lectures on Veterinary Vaccine Development by Leaders from Major Participants
- Topic 502: Rapid vaccination to control zoonotic infectious diseases
- Session 503: Introducing a New Generation of Veterinary Vaccines
- Topic 504: Antiviral and antibacterial fish vaccines
- Session 6: Development of clinical trials for vaccines
- Topic 600: Evaluation of clinical efficacy and safety of vaccines
- Topic 601: Thoughts on personalized medicine for clinical cancer vaccines
- Topic 602: Clinical, disease control in response to public health events
- Session 7: Production, manufacturing and quality control / quality assurance of vaccines
- Session 8: Youth Forum
- Session 8-1: Bioinformatics, Genomics, Proteomics in Vaccine Design Research
- Session 8-2: Cell-based vaccine research for attenuated and inactivated research
- Session 8-3: Research on Baculovirus / Insect Cell Expression Systems
- Session 8-4: DNA / rDNA Vaccine Design and Generation
- Topic 8-5: Research on vaccine conjugates, subunits, and adjuvants
- Session 8-6: Studies on Immunity Legal, Safety, and Ethical Issues Nearing Public Acceptance
- Session 9: Lectures and Training
- Topic 900: How to Write a High-Quality SCI Journal Article
- Topic 901: Preparation and prevention of pandemic influenza vaccine
- Topic 902: How to implant a therapeutic vaccine in a hospital
- Topic 903: Nursing and clinical management of vaccination side effects
- 1) Human vaccines: hepatitis B vaccine, hepatitis A vaccine, rabies vaccine, influenza vaccine, meningococcal vaccine, Japanese encephalitis vaccine, pneumonia vaccine, tuberculosis vaccine, AIDS vaccine, bird flu vaccine, cervical cancer vaccine rotavirus vaccine, SARS vaccine, etc .
- 2) Animal vaccines: animal vaccines such as dog vaccines, cat vaccines, vaccine production equipment, transportation equipment, storage equipment.
- 3) Poultry vaccines: chicken, duck, goose, pig, cattle, and sheep vaccines.
- 4) Others: vaccine testing equipment, vaccine research institutions, vaccine websites, books and periodicals.
|
